| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Isabelle Austin-Zimmerman, Edoardo Spinazzola, Diego Quattrone, Beatrice Wu-Choi, Giulia Trotta, Zhikun Li, Emma Johnson, Alexander L Richards, Tom P Freeman, Giada Tripoli, Charlotte Gayer-Anderson, Victoria Rodriguez, Hannah E Jongsma, Laura Ferraro, Caterina La Cascia, Sarah Tosato, Ilaria Tarricone, Domenico Berardi, Elena Bonora, Marco Seri, Giuseppe D'Andrea, Andrei Szöke, Celso Arango, Julio Bobes, Julio Sanjuán, Jose Luis Santos, Manuel Arrojo, Eva Velthorst, Miguel Bernardo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B Jones, James B Kirkbride, Bart P F Rutten, Andrea Tortelli, Pierre-Michel Llorca, Lieuwe de Haan, Simona Stilo, Daniele La Barbera, Antonio Lasalvia, Franck Schurnhoff, Baptiste Pignon, Jim van Os, Michael Lynskey, Craig Morgan, Michael O' Donovan, Cathryn M Lewis, Pak C Sham, Robin M Murray, Evangelos Vassos, Marta Di Fort. The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies. Psychological medicine. 2024-12-05. PMID:39637925. |
the impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the eu-gei case-control and uk biobank studies. |
2024-12-05 |
2024-12-08 |
Not clear |
| Isabelle Austin-Zimmerman, Edoardo Spinazzola, Diego Quattrone, Beatrice Wu-Choi, Giulia Trotta, Zhikun Li, Emma Johnson, Alexander L Richards, Tom P Freeman, Giada Tripoli, Charlotte Gayer-Anderson, Victoria Rodriguez, Hannah E Jongsma, Laura Ferraro, Caterina La Cascia, Sarah Tosato, Ilaria Tarricone, Domenico Berardi, Elena Bonora, Marco Seri, Giuseppe D'Andrea, Andrei Szöke, Celso Arango, Julio Bobes, Julio Sanjuán, Jose Luis Santos, Manuel Arrojo, Eva Velthorst, Miguel Bernardo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B Jones, James B Kirkbride, Bart P F Rutten, Andrea Tortelli, Pierre-Michel Llorca, Lieuwe de Haan, Simona Stilo, Daniele La Barbera, Antonio Lasalvia, Franck Schurnhoff, Baptiste Pignon, Jim van Os, Michael Lynskey, Craig Morgan, Michael O' Donovan, Cathryn M Lewis, Pak C Sham, Robin M Murray, Evangelos Vassos, Marta Di Fort. The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies. Psychological medicine. 2024-12-05. PMID:39637925. |
we used data from the eu-gei case-control study and uk biobank to examine the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (prs) on risk for psychosis. |
2024-12-05 |
2024-12-08 |
Not clear |
| Ida Margrethe Nielsen, Lisbeth Uhrskov Sørensen, Søren Wichmand, Parnûna Heilmann, Michael Lynge Pederse. Substance use and lifestyle risk factors for somatic disorders among psychiatric patients in Greenland. International journal of circumpolar health. vol 83. issue 1. 2024-10-27. PMID:39462457. |
this study revealed a notable prevalence of risk factors for somatic diseases, particularly smoking and cannabis use among patients with schizophrenia in nuuk, indicating that a high prevalence of somatic diseases might be expected as the population gets older and the risk of developing somatic diseases becomes greater. |
2024-10-27 |
2024-10-30 |
Not clear |
| Chungah Kim, Yihong Bai, Peiya Cao, Kristine Ienciu, Antony Chu. The impact of recreational cannabis legalization on cannabis-related acute care events among adults with schizophrenia. Social psychiatry and psychiatric epidemiology. 2024-10-10. PMID:39387895. |
the impact of recreational cannabis legalization on cannabis-related acute care events among adults with schizophrenia. |
2024-10-10 |
2024-10-13 |
Not clear |
| Chungah Kim, Yihong Bai, Peiya Cao, Kristine Ienciu, Antony Chu. The impact of recreational cannabis legalization on cannabis-related acute care events among adults with schizophrenia. Social psychiatry and psychiatric epidemiology. 2024-10-10. PMID:39387895. |
patients with schizophrenia have a higher risk of cannabis use disorder and may be uniquely affected by the legalization of recreational cannabis. |
2024-10-10 |
2024-10-13 |
Not clear |
| Chungah Kim, Yihong Bai, Peiya Cao, Kristine Ienciu, Antony Chu. The impact of recreational cannabis legalization on cannabis-related acute care events among adults with schizophrenia. Social psychiatry and psychiatric epidemiology. 2024-10-10. PMID:39387895. |
this study examined whether cannabis legalization led to changes in acute care utilization among patients with schizophrenia. |
2024-10-10 |
2024-10-13 |
Not clear |
| Dan Siskind, Claudia Bull, Shuichi Suetani, Nicola Warren, Anastasia Suraev, Iain McGregor, Steve Kisely, Veronica De Monte, Mike Trott, Manju Shine, Vikas Moudgil, Gail Robinson, Stephen Parker, Ravikumar Krishnaiah, Terry Stedman, Allan Drummond, Sarah Medland, Ravi Iyer, Andrea Bake. Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia. BJPsych open. vol 10. issue 5. 2024-10-03. PMID:39359160. |
protocol for cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia. |
2024-10-03 |
2024-10-05 |
Not clear |
| Dan Siskind, Claudia Bull, Shuichi Suetani, Nicola Warren, Anastasia Suraev, Iain McGregor, Steve Kisely, Veronica De Monte, Mike Trott, Manju Shine, Vikas Moudgil, Gail Robinson, Stephen Parker, Ravikumar Krishnaiah, Terry Stedman, Allan Drummond, Sarah Medland, Ravi Iyer, Andrea Bake. Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia. BJPsych open. vol 10. issue 5. 2024-10-03. PMID:39359160. |
cannabidiol (cbd) reduces positive symptoms in individuals with schizophrenia, but no trials have specifically examined its efficacy in those with clozapine-resistant schizophrenia. |
2024-10-03 |
2024-10-05 |
Not clear |
| Nestor Szerman, Pablo Vega, Carlos Roncero, Lola Peris, Lara Grau-López, Ignacio Basurte-Villamo. Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. International clinical psychopharmacology. 2024-09-25. PMID:39319529. |
cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. |
2024-09-25 |
2024-09-27 |
Not clear |
| Nestor Szerman, Pablo Vega, Carlos Roncero, Lola Peris, Lara Grau-López, Ignacio Basurte-Villamo. Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. International clinical psychopharmacology. 2024-09-25. PMID:39319529. |
schizophrenia is often associated with substance use disorders, particularly cannabis use disorder (cud). |
2024-09-25 |
2024-09-27 |
Not clear |
| Mark J H Lim, Rajan Iyyalol, Joseph W Y Lee, Mathew T Martin-Iverso. Multi-modal and bi-directional effects of a synthetic Δ9-Tetrahydrocannabinol (THC) analogue, Nabilone, on spatio-temporal binding windows: Evidence from the projected hand illusion. PloS one. vol 19. issue 9. 2024-09-09. PMID:39250476. |
the literature claims either pro-psychotic or anti-psychotic effects of Δ9-tetrahydrocannabinol (thc) in patients and healthy individuals, but major support for cannabis in the aetiology of schizophrenia is associative, not causal. |
2024-09-09 |
2024-09-13 |
human |
| Charalampos Brakatselos, Alexia Polissidis, George Ntoulas, Michail-Zois Asprogerakas, Olga Tsarna, Anastasia Vamvaka-Iakovou, Gerasimos Nakas, Anastasios Delis, Petros Tzimas, Leandros Skaltsounis, Joana Silva, Foteini Delis, Joao Filipe Oliveira, Ioannis Sotiropoulos, Katerina Antonio. Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-09-06. PMID:39242923. |
multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. |
2024-09-06 |
2024-09-10 |
rat |
| Özge Türkoğlu, Aygün Ertuğru. The Role of Cannabis in the Development of Psychosis. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 35. issue 3. 2024-09-03. PMID:39224996. |
additionally, evidence that dysfunctions in the endocannabinoid system play a role in the etiology of schizophrenia suggests that cannabis affects the disease process by worsening existing dysfunctions in this system. |
2024-09-03 |
2024-09-05 |
Not clear |
| Tyler A Lesh, Joshua Rhilinger, Rylee Brower, Alex M Mawla, J Daniel Ragland, Tara A Niendam, Cameron S Carte. Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia. Schizophrenia bulletin open. vol 5. issue 1. 2024-08-15. PMID:39144106. |
using task-fmri to explore the relationship between lifetime cannabis use and cognitive control in individuals with first-episode schizophrenia. |
2024-08-15 |
2024-08-17 |
Not clear |
| Tyler A Lesh, Joshua Rhilinger, Rylee Brower, Alex M Mawla, J Daniel Ragland, Tara A Niendam, Cameron S Carte. Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia. Schizophrenia bulletin open. vol 5. issue 1. 2024-08-15. PMID:39144106. |
while continued cannabis use and misuse in individuals with schizophrenia is associated with a variety of negative outcomes, individuals with a history of use tend to show higher cognitive performance compared to non-users. |
2024-08-15 |
2024-08-17 |
Not clear |
| Tyler A Lesh, Joshua Rhilinger, Rylee Brower, Alex M Mawla, J Daniel Ragland, Tara A Niendam, Cameron S Carte. Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia. Schizophrenia bulletin open. vol 5. issue 1. 2024-08-15. PMID:39144106. |
forty-eight first-episode individuals with schizophrenia (fes) with a history of cannabis use (fes + can), 28 fes individuals with no history of cannabis use (fes-can), and 59 controls (con) performed the ax-continuous performance task during fmri. |
2024-08-15 |
2024-08-17 |
Not clear |
| Garrison J B Dyck, Zaid H Maayah, Dean T Eurich, Jason R B Dyc. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144756. |
understanding the potential benefits of cannabidiol for patients with schizophrenia: a narrative review. |
2024-08-15 |
2024-08-17 |
Not clear |
| Garrison J B Dyck, Zaid H Maayah, Dean T Eurich, Jason R B Dyc. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144756. |
however, studies have shown that another major cannabinoid found in cannabis, cannabidiol (cbd), may be a potential alternative or adjunctive treatment for psychosis and schizophrenia. |
2024-08-15 |
2024-08-17 |
Not clear |
| Zhikun Li, Diptendu Mukherjee, Bea Duric, Isabelle Austin-Zimmerman, Giulia Trotta, Edoardo Spinazzola, Diego Quattrone, Robin M Murray, Marta Di Fort. Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents. Molecular psychiatry. 2024-08-01. PMID:39090371. |
the link between cannabis use and schizophrenia is well-established in epidemiological studies, especially among adolescents with early-onset use. |
2024-08-01 |
2024-08-05 |
Not clear |
| Jes Sebastian Denis Völker, M D Ph D Ioana Valentina Micluția, Ramona-Cristina Vinaș. Investigating Cannabidiol's Potential as a Supplementary Treatment for Schizophrenia: A Narrative Review. European journal of pharmacology. 2024-07-28. PMID:39068976. |
cannabidiol (cbd), a nonpsychoactive compound in cannabis sativa, has been extensively explored for its therapeutic potential in treating psychiatric disorders, including schizophrenia. |
2024-07-28 |
2024-08-02 |
Not clear |